Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Would you stop methotrexate or Leflunomide if MCV increases after starting the medication's with no other parameters of anemia or leukopenia
Related Questions
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
How do you approach choosing between subcutaneous and IV actemra for RA?
How would you manage a patient with severe deforming seronegative RA who has failed or been intolerant to DMARDs, TNFi, abatacept, Jak inhibitors, IL-6 and IL-1 agents in addition to Rituxan and moderate dose prednisone?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How do you approach diagnosis in a patient with inflammatory joint symptoms and isolated bilateral CMC joint erosions on x-ray imaging?
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
